Healthcare Industry News: cardiac PET
News Release - October 17, 2007
Positron Introduces New Attrius(TM) Cardiac PET Scanner at the Annual Meeting of the American Society of Nuclear CardiologyHOUSTON--(HSMN NewsFeed)--Positron Corporation (OTCBB:POSC ) introduced their new dedicated cardiac PET system at the annual meeting of the American Society of Nuclear Cardiology. The meeting attendees consisted of more than 1,500 nuclear cardiologists, practice administrators and technologists with the majority operating myocardial perfusion imaging with private cardiology practices.
Positron's new Attrius(TM) molecular imaging system incorporates patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Positron Corporation offers a unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers.
Positron's refocus on cardiology has taken them back to their original core competency which is providing cardiologists with superior imaging tools combined with disease specific software solutions. Market dynamics have changed dramatically since 1983 when the company offered their first cardiac device. The proposed increase in reimbursement in the face of the deficit reduction act, the introduction of new peer reviewed literature suggesting the cost effective benefit of cardiac PET imaging combined with Positron's market entry of a cost effective PET only solution are clear indications of new market development.
Positron Corporation's President, Joseph Oliverio stated, "The Attrius(TM) is the only dedicated cardiac PET scanner on the market, which positions the Company in a unique market ascendancy point. Market dynamics combined with our cost effective scanner offering will allow the Company to seize a leading market position as a unique niche player in the nuclear cardiology market segment with virtually no other company offering such a comprehensive solution."
Positron Corporation designs, manufactures, markets and supports advanced cardiac molecular imaging devices utilizing single photon emission computed tomography (SPECT) and positron emission tomography (PET). The company's molecular imaging systems incorporate patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. Additional information may be found at http://www.positron.com and http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Source: Positron Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.